Cantor Fitzgerald Issues Positive Outlook for VYGR Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Voyager Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will earn ($2.03) per share for the year, up from their previous forecast of ($2.20). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share.

Several other equities research analysts also recently commented on VYGR. Wedbush reissued an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday. Citigroup began coverage on Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price on the stock. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Canaccord Genuity Group dropped their target price on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Voyager Therapeutics has an average rating of “Buy” and a consensus target price of $14.86.

Voyager Therapeutics Stock Up 0.2 %

Shares of VYGR stock opened at $4.07 on Friday. The business’s fifty day moving average is $4.91 and its 200 day moving average is $5.86. Voyager Therapeutics has a twelve month low of $3.56 and a twelve month high of $10.66. The stock has a market cap of $222.33 million, a price-to-earnings ratio of 5.73 and a beta of 0.99.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The firm had revenue of $4.39 million during the quarter, compared to analysts’ expectations of $16.58 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the previous year, the company earned $1.25 earnings per share.

Insider Activity

In other news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 10,778 shares of company stock valued at $58,548 over the last ninety days. 4.53% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock valued at $6,316,000 after acquiring an additional 6,740 shares during the period. FMR LLC lifted its holdings in Voyager Therapeutics by 26.9% in the third quarter. FMR LLC now owns 92,498 shares of the company’s stock valued at $541,000 after acquiring an additional 19,622 shares during the period. Barclays PLC lifted its holdings in Voyager Therapeutics by 55.8% in the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after acquiring an additional 37,398 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Voyager Therapeutics by 23.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock valued at $223,000 after acquiring an additional 7,573 shares during the period. Finally, Verition Fund Management LLC bought a new position in Voyager Therapeutics in the third quarter valued at about $216,000. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.